Selecting the Right CRO for a Phase 2 Orphan Disease CNS Study

Seuss+ supported a privately owned, early-stage biotech in selecting the right CRO for a Phase 2 orphan disease CNS study through a structured, data-driven selection process. By leading the RFI, RFP, and bid defense, managing CRO communications, and supporting contract negotiations, we helped the sponsor make a well-informed decision without disrupting study start-up timelines.

Summary

A privately owned, early-stage biotech focused on CNS therapies was preparing for a Phase 2 orphan disease study.

With study start-up approaching, the sponsor needed to identify a CRO that could meet the specific needs of the trial and establish the right operational and commercial model for the partnership.

The selection process also needed to be rigorous and fully documented. The sponsor wanted a clear record of how potential CROs had been assessed and why the final decision had been made, giving internal stakeholders and the Board confidence in the selection.

We designed and co-ordinated the process from the initial RFI through RFP, bid defense, and contracting. We assessed different partnership models, managed CRO communications, documented decision-making, and supported negotiations across the SUA, MSA, and Work Order.

The sponsor selected its CRO within four months and achieved first patient in according to the planned study timeline.

Clinical Trial Success in CNS
4
Months to select a CRO
3
agreements supported through negotiation
2
commercial controls established: payment terms and KPIs

What Seuss+ Delivered

A Structured CRO Selection and Contracting Process We designed and managed a CRO selection process around the specific needs of the sponsor and its Phase 2 orphan disease CNS study.

The work began with a structured RFI to assess potential CRO partners before moving into the RFP and bid defense stages. We co-ordinated the evaluation process, giving the sponsor a consistent way to compare potential partners and the information needed to make a well-supported decision.

We also assessed different partnership models to identify the model best suited to the study and the sponsor’s needs.

Throughout the process, we managed communications with the CROs and documented the evaluation and decision-making, creating a clear record of how the selected CRO was appointed.

Once the CRO had been selected, we supported negotiations across the SUA, MSA, and Work Order, including payment terms and KPIs designed to strengthen CRO accountability during study delivery.

The Risk/Challenge

M

The sponsor was preparing for a Phase 2 orphan disease CNS study and needed to identify the right CRO partner

M

As a small, early-stage biotech, the sponsor needed a structured selection process without slowing study start-up

M

Potential CROs and partnership models needed to be assessed consistently

M

The sponsor needed clear documentation behind the final selection decision

M

Internal stakeholders and the Board needed confidence in how the CRO had been selected

M

CRO communications, evaluations, and decision-making needed to be recorded throughout the process

M

Contract negotiations needed to support clear expectations and CRO accountability

M

Selection and contracting activities needed to progress without disrupting the planned study timeline

The Results

N

The sponsor selected its CRO within four months

N

First patient in was achieved according to the planned study timeline

N

Different partnership models were evaluated before the model best suited to the study was selected

N

The sponsor gained a consistent, data-led basis for comparing potential CRO partners

N

Internal stakeholders were aligned around the final CRO selection

N

The sponsor and its Board had a clear record supporting how and why the CRO had been selected

N

The CRO evaluation and selection process was fully documented to support audit and inspection readiness

N

Sponsor-friendly contractual terms were negotiated across the SUA, MSA, and Work Order

N

Payment terms and KPIs were established to support CRO accountability during study delivery

How We Helped

Designed a structured RFI process to assess potential CRO partners

Co-ordinated the end-to-end CRO selection process

Developed and managed the RFP

Co-ordinated the bid defense process

Created a consistent framework for comparing potential CRO partners

Evaluated different partnership models with the sponsor

Managed communications with participating CROs throughout the selection

Documented evaluations and decision-making to create a clear audit trail

Supported internal stakeholder alignment around the final CRO selection

Supported negotiations following CRO appointment

Negotiated the SUA, MSA, and Work Order

Helped establish payment terms and KPIs to support CRO accountability

Kept selection and contracting activities aligned with the wider study timeline

Frequently Asked Questions

Choosing a CRO can have a direct impact on study timelines, costs, and operational delivery. A structured process gives the sponsor a consistent way to assess potential partners against the specific needs of the study, rather than relying on reputation, existing relationships, or headline proposals. It also creates a clear record of why the final decision was made.

Yes. We can support the process from the initial RFI and RFP through CRO evaluation, bid defense, decision-making, and contract negotiation. This gives the sponsor continuity throughout the selection process while allowing the internal team to stay focused on the wider clinical development program.

CRO selection and contracting need to be planned alongside the wider study timeline. In this case, we co-ordinated the RFI, RFP, bid defense, decision-making, and contracting activities so the sponsor could select its CRO within four months and achieve first patient in according to plan.

Schedule a consultation now

 

Key Takeaways

  • A privately owned, early-stage biotech preparing a Phase 2 orphan disease CNS study needed the right CRO before study start-up, with a fully documented decision its Board could stand behind.
  • Seuss+ ran the full process from RFI through RFP, bid defense, and contracting, managing every CRO communication and evaluating different partnership models along the way.
  • The sponsor selected its CRO within four months and achieved first patient in according to the planned study timeline.
  • Sponsor-friendly terms were negotiated across the SUA, MSA, and Work Order, including payment terms and KPIs that tie CRO performance to study delivery.
  • Every evaluation and decision was documented, giving the Board a clear record of why the CRO was chosen and supporting audit and inspection readiness.

Choosing a CRO is one of the biggest decisions an early-stage biotech makes, and it almost always happens under time pressure. A structured process does not slow you down. It is what lets you move quickly and still show your Board exactly why you chose the partner you did.

Kieran Engels, CEO and Co-Founder of Seuss+

Choosing a CRO for your next study?

Book a 30-minute call. We will walk through how a structured RFI, RFP, and bid defense process would work for your trial and your timeline.

Book an intro call